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ABSTRACT 21 
Background: Photodynamic therapy (PDT) has been long used to treat localized 22 
tumors and infections. Currently, microbial inactivation data is reported presenting 23 
survival fraction averages and standard errors as discrete points instead of a 24 
continuous curve of inactivation kinetics. Standardization of this approach would 25 
allow clinical protocols to be introduced globally, instead of the piecemeal situation 26 
which currently applies.  27 
Methods: To this end, we used a power-law function to fit inactivation kinetics and 28 
directly report values of lethal doses (LD) and a tolerance factor (T) that informs if 29 
inactivation rate varies along the irradiation procedure. A deduced formula was also 30 
tested to predict LD for any given survival fraction value. We analyzed the 31 
photoantimicrobial effect caused by red light activation of methylene blue (MB-32 
APDT) and by blue light (BL) activation of endogenous microbial pigments against 5 33 
clinically relevant pathogens. 34 
Results:  Following MB- APDT, E. coli and S. aureus cells become increasingly 35 
more tolerant to inactivation along the irradiation process (T<1). K. pneumoniae 36 
presents opposite behavior, i.e., more inactivation is observed towards the end of the 37 
process (T>1). P. aeruginosa and C. albicans present constant inactivation rate 38 
(T~1). In contrast, all bacterial species presented similar behavior during inactivation 39 
caused by BL, i.e., continuously becoming more sensitive to blue light exposure 40 
(T>1).  41 
Conclusion: The power-law function successfully fit all experimental data. The 42 
analytical model precisely predicted LD and T values. We expect that these 43 
analytical models may contribute to more standardized methods for comparisons of 44 
photodynamic inactivation efficiencies. 45 
 46 
Keywords: bacteria; fungi; mathematical analysis; microbial control; 47 
photoantimicrobial; photoinactivation; photodynamic antimicrobial chemotherapy.  48 
  49 
Introduction 50 
 51 
 Photodynamic therapy (PDT) has been long studied and used to treat 52 
localized tumors and infections (1, 2). This light-based technology platform produces 53 
cytotoxic molecular species in a space-time controlled manner, i.e., in the absence of 54 
light, photosensitizer (PS) or oxygen, photodynamic reactions do not occur. The 55 
light-excited PS interacts with molecular oxygen, either by charge (type I reaction) or 56 
energy donation (type II reaction), forming a variety of reactive oxygen species 57 
(ROS) that can destroy bacteria, parasites, fungi, algae and viral particles (2-7). 58 
 The use of PSs thus offers an effective local – not just topical – approach to 59 
infection control, often termed antimicrobial photodynamic therapy (APDT). 60 
Importantly, the agency of ROS here means that the conventional resistance status 61 
of the microbial target is unimportant.  However, in order to provide 62 
photosensitization that is fit for purpose, the killing effects of PSs require proper 63 
quantification and benchmarking, e.g., the PS concentration and light dose required 64 
to destroy a given microbial burden at a certain rate. Standardization of this 65 
approach would allow clinical protocols to be introduced globally, instead of the 66 
piecemeal situation which currently applies. 67 
 According to the Second Law of Photochemistry, for each photon absorbed by 68 
a chemical system, only one molecule can be excited and subsequently undergo a 69 
photochemical reaction. Based on this principle, current literature supports 70 
photodynamic dosimetry in respect of the number of absorbed photons (Absorbed 71 
Photons/cm3 instead of J/cm2) to provide a rather interpretable comparison of PS 72 
efficiency (8, 9). It has been proposed that using this method, problematic dosimetry 73 
due to variable PS concentration, optical path and excitation wavelength band can 74 
be minimized. However, some other problematic situations can be addressed by this 75 
method as well. If a filter effect is caused either by high cellular and/or PS 76 
concentrations, absorbed photon results may lead to divergent interpretations. Also, 77 
Prates et al. (10) have demonstrated that if the number of absorbed photons is kept 78 
constant but irradiance varies, the level of microbial inactivation also diverges (10). 79 
These situations suggest the need for a more robust standard method, even though 80 
the number of absorbed photons per unit volume can be considered to represent an 81 
improvement on merely reporting inactivation as a function of radiant exposure. 82 
 Currently, the most accepted form of reporting microbial inactivation data in 83 
scientific articles is presenting survival fraction averages and standard errors as 84 
discrete points instead of a continuous curve of inactivation kinetics (9, 10). However, 85 
analysis of variance over individual points only allows the interpretation of whether 86 
those points present statistically significant differences among themselves. 87 
Therefore, if one intends to compare the potency of a set of variable antimicrobial 88 
photodynamic systems (i.e., different PSs, microbial species, light sources, etc.) this 89 
analysis may be misguided by local observation of a single point instead of the 90 
interpretation of a global kinetics rate. Therefore, this analytical method may lead to 91 
false-positive or -negative interpretations in respect to the overall phenomena of 92 
microbial inactivation kinetics. 93 
 To this end, we report a simple mathematical analysis of continuous bacterial 94 
inactivation kinetics curves. We analyzed the photodynamic killing effect caused by 95 
red light activation of methylene blue (MB) and by blue light activation of 96 
endogenous microbial photosensitive pigments. We expect that this method may 97 
assist in developing standardized and more insightful analysis of photoantimicrobial 98 
systems. 99 
 100 
Material and Methods 101 
 102 
APDT experiments  103 
 In the present study we used the following strains from the American Type 104 
Culture Collection (ATCC): Escherichia coli (ATCC 25922), Staphylococcus aureus 105 
(ATCC 25923), Klebsiella pneumoniae (ATCC 700603), Pseudomonas aeruginosa 106 
(ATCC 27853) and Candida albicans (ATCC 90028).  107 
 Standard APDT susceptibility testing was carried out based on Prates et al. 108 
(10). Inocula were prepared from log-phase overnight cultures. The turbidity of cell 109 
suspensions was measured in a spectrophotometer to obtain inocula at McFarland 110 
scale 0.5. The scale was calibrated to obtain an optical density of 0.09 at 540 nm and 111 
625 nm resulting in 1-2 x 106 CFU/mL of fungi cells, and 1-2 x 108 CFU/mL of 112 
bacterial cells, respectively. Inocula were diluted to a working concentration of 1-2 x 113 
105 CFU/mL of fungi or 1-2 x 107 CFU/mL of bacteria. 114 
 MB hydrate (purity > 95%, Sigma-Aldrich, USA) was employed as the 115 
exogenous PS for this study. Before irradiation, cells were incubated with 100 µM of 116 
MB in phosphate-buffered saline (PBS) for 10 min at room temperature and in the 117 
dark, to allow initial uptake. One-mL aliquots were individually placed in clean wells 118 
of a 12-well microplate. To avoid cross light exposure, each sample was kept in 119 
individual microtubes in the dark during pre-irradiation time and placed in the 12-120 
wells plate only for irradiation. 121 
 A red LED probe (660 ± 10 nm, Prototype 1, BioLambda, Brazil) was 122 
positioned perpendicularly above each sample, keeping the beam diameter at the 123 
bottom of the well at 25 mm (which coincides to a single well diameter from the 12-124 
wells plate). Red light irradiance was kept constant at 100 mW/cm2 and radiant 125 
exposure levels varied according to each microbial species sensitivity to MB-APDT 126 
as previously determined in pilot experiments. 127 
A blue LED irradiator (415 ± 12 nm, LEDbox, BioLambda, Brazil) was placed 128 
below 12-well plates containing 1 mL of each microbial sample. In this case, no 129 
exogenous PS was added to the systems. Blue light irradiance was kept constant at 130 
38.2 mW/cm2. Radiant exposure levels varied according to each microbial species 131 
sensitivity to blue light inactivation as previously determined in pilot experiments.  132 
Immediately after each irradiation process, bacterial suspensions were serially 133 
diluted in PBS to give dilutions from 10-1 to 10-6 times the original concentration. Ten-134 
µL aliquots of each dilution were streaked onto Mueller-Hinton agar plates, in 135 
triplicate, and incubated at 37° C overnight. A similar procedure was performed for 136 
fungi. However, in this case dilutions were between 10-1 - 10-4-fold and streaked onto 137 
Sabouraud dextrose agar. The colonies were counted and converted into CFU/mL 138 
for survival fraction analysis. 139 
 140 
Data analysis 141 
 We adapted a power law function to fit inactivation kinetics data in respect to 142 
variable radiant exposure levels (equation 1). Theoretical lethal dose (LD) for any 143 
given inactivation rate (i.e., % of bacterial survival fraction) was calculated according 144 
to equation 2. Fitting, residuals and derivatives were calculated using the Prism 7.0 145 

















 Equation 2 
where: 147 
N0= initial microbial burden; N= final microbial burden; Dose= light exposure (e.g. J, 148 
J/cm2, time units, Absorbed Photons/cm3, etc.); LD90= lethal dose for 90% of 149 
microbial burden (in light exposure units); T= tolerance factor; i= inactivation 150 
percentage (%). 151 
 152 
 Unfortunately, data analysis softwares may not have equations 1-2 as 153 
standard models for fitting data. In Prism 7.0, we added equation 1 as an explicit 154 
equation for non-linear regression (curve fit) analysis in the following formula: 155 
Y=(x/LD90)^(T). Initial values for data fit of LD90 and T were set as 1.  LDs were 156 
calculated by Microsoft Excel 2018 using LD90 and T values obtained from equation 157 
1. The LD99.9 and LD100 values were then calculated for each dataset using equation 158 
2 in the following formula: =(LD90)*(-LOG10(1-(i/100)))^(1/T).  159 
 Experiments were performed at least in triplicates. Quantitative data are 160 
presented as log10 of normalized means and standard error of means calculated in 161 
relation to the respective control groups. Survival fraction data were analyzed by 162 
Shapiro-Wilk test to confirm normality. Fitted curves were analyzed using F-test to 163 
check if any of the fitted curves are shared in between different species. Lethal-dose 164 
and T value analysis were compared in between species using one-way analysis of 165 
variance (ANOVA) with Bonferroni as post-hoc test for multiple comparisons. Results 166 
were considered significant if p < 0.05.  167 
 168 
Results and Discussion 169 
  170 
 The Weibull analysis is a well-known and accepted statistical method that 171 
uses a power-law function to describe breakdown kinetics of various materials. This 172 
analysis assumes that the survival curve is affected by cumulative distributions of 173 
damages that leads to lethal effects. Here we assumed that it properly describes 174 
effects such as the cumulative oxidative damage imposed by APDT over living cells 175 
(11).  176 
 Historically, this statistical model has been mostly employed in industries, 177 
such as aerospace and automotive, to estimate the reliability on lifespan of 178 
mechanical parts (12). This mathematical function has been used to describe bacterial 179 
inactivation kinetics during thermal inactivation or gamma radiation, UV- and blue-180 
light irradiation, free of exogenous PSs (13-16). However, it has not so far been 181 
proposed as a method to standardize APDT sensitivity protocols. 182 
 Power-Law fit appears to represent a very good description for APDT 183 
inactivation kinetics of our data. Adjusted R2 values always fluctuated above 0.95 184 
(Table 1). These values represent very good results in relation to general non-linear 185 
curve fittings.  186 
 187 
Table 1. Adjusted R2 value of each non-linear curve fit 188 
Species E. coli S. aureus P. aeruginosa K. pneumoniae C. albicans 
MB-APDT 0.9745 0.9955 0.9939 0.9834 0.9793 
Blue Light 0.9691 0.9518 0.9805 0.9526 0.9756 
  189 
 The F-test applied over non-linear regressions reported that each species 190 
dataset presents a unique inactivation kinetics curve (fig. 1a-b). This means that 191 
even though some inactivation data points may not present statistical differences in 192 
between species, the entire inactivation kinetics are not the same. 193 
 The first derivative of inactivation curves (fig. 1c-d) further illustrates the 194 
variation in inactivation rates. This analysis shows how fast the inactivation occurs 195 
during the irradiation procedure. For MB-APDT, E. coli and S. aureus cells are 196 
inactivated rapidly in the beginning of the procedure but slower towards the end of 197 
the process. K. pneumoniae presents the exact opposite behavior. P. aeruginosa 198 
and C. albicans, however, present almost a constant inactivation rate. On the other 199 
hand, all bacterial species presented similar behavior during inactivation caused by 200 
blue light alone, i.e., slow initial inactivation but becoming continuously more 201 
sensitive to blue light exposure. Conversely, C. albicans presented again almost a 202 
constant inactivation rate. 203 
 204 
 205 
Figure 1. Inactivation kinetics plots. On the top, survival fraction values are 206 
presented for (a) MB-APDT and (b) blue light photoinactivation. Below are the first 207 
derivatives (i.e., microbial inactivation rate) of each non-linear regression curves 208 
fitted for (c) MB-APDT and (d) blue light photoinactivation. The experimental data 209 
from a and b are the log reduction of normalized survival fraction and standard 210 
errors. 211 
 212 
 We also submitted inactivation data to double-log transformations in order to 213 
confirm data linearization. This is a standard empirical method used to confirm the 214 
feasibility of a power-law fit in experimental datasets. As a matter of fact, successful 215 
linearization (fig. 2a-b) further proves the ability to describe photoinactivation 216 
kinetics assuming a Power-Law behavior, yet all residual dispersions presented 217 
random distributions (fig. 2c-d). 218 
  219 
 220 
Figure 2. Linearization of inactivation kinetics data by double-log transformations in 221 
a and b confirms the hypothesis of power law function fitting. Residuals of fitted data 222 
in c and d presented random distributions around the average, confirming data 223 
homogeneity and normality. 224 
 225 
 Non-linear regression results are presented in figure 3 as values of the 226 
tolerance factor T and lethal doses for 90 percent (1log10) of inactivation. The 227 
tolerance factor T informs the concavity of the inactivation curves; if T>1, cells are 228 
initially tolerant to APDT but become increasingly sensitive; if T<1, cells are initially 229 
very sensitive, but some persistent cells remain more tolerant to inactivation. Hence, 230 
the behavior observed at the inactivation rate curves (fig. 1c-d) can be indicated by 231 
the T values (fig. 3a-b).  232 
 For MB-APDT (fig. 3a), S. aureus and E. coli T<1 with no statistically 233 
significant difference among themselves; P. aeruginosa and C. albicans presented T 234 
values close to 1, with no statistical difference among themselves; K. pneumoniae 235 
presented a T value close to 1.5 and was statistically different from all other species 236 
treated by MB-APDT. For blue light inactivation, all species presented T values 237 
above 1, without any statistically significant differences in between them. These 238 
statistical analysis results are presented in tables 2-3 in supplementary material. 239 
 240 
 241 
Figure 3. Non-linear regression parameters of inactivation kinetics obtained for each 242 
tested species. On the top, T values are presented for (a) MB-APDT and (b) blue 243 
light photoinactivation. Below are the LD90 values calculated for (c) MB-APDT and 244 
(d) blue light photoinactivation. The presented values are means of constants and 245 
standard errors directly obtained by power law non-linear regressions. 246 
 247 
 Lethal doses for 90% (i.e., 1 log10) inactivation with MB-APDT (fig. 3c) show 248 
that E. coli and S. aureus are the most sensitive and present statistically significant 249 
differences to all other species but not among themselves. P. aeruginosa presented 250 
an intermediate sensitivity to MB-APDT that was significantly different from all other 251 
species. K. pneumoniae and C. albicans are significantly more tolerant to MB-APDT 252 
than all other species but not amongst themselves. Even though no statistical 253 
differences were observed for T values of blue light inactivation (fig. 3d), several 254 
particularities were reported for lethal dose values. E. coli and S. aureus are quite 255 
sensitive to blue light and present statistically similar behavior. However, P. 256 
aeruginosa seems to be the most sensitive species tested to blue light, although it 257 
did not show statistically significant differences relative to S. aureus. Such high 258 
sensitivity of P. aeruginosa to blue light may be linked to high yield production of 259 
pyoverdine, a naturally occurring fluorescent pigment that strongly absorbs 415 nm 260 
light and may undergo photodynamic reactions (17, 18). K. pneumoniae and C. 261 
albicans are significantly the most tolerant species to blue light and do not present 262 
statistical differences between themselves. These statistical results can be seen in 263 
tables 4-5 from supplementary material.  264 
 The concept of inactivation rate illustrated by the first derivative of inactivation 265 
curves can be specifically quantified by the tolerance factor, presented as T values 266 
(fig. 3a). This is a dimensionless value that indicates the overall inactivation rate 267 
behavior. It describes whether cells are more tolerant to inactivation at the beginning 268 
of the irradiation process or at the end. Therefore, we can indicate the existence of 269 
microbial species with a constitutive tolerance (T>1) that is soon depleted making 270 
cells become increasingly sensitive (e.g., MB-APDT for E. coli and S. aureus); or the 271 
presence of adapting or more persistent cells (T<1) that remain harder to kill after a 272 
period of irradiation (e.g., blue light for bacteria). Microbial species with T values 273 
close to unity may represent an intermediate situation (e.g., C. albicans in both 274 
situations). The exact tolerance mechanisms responsible for these inactivation 275 
kinetics variations may have a multifactorial basis that leads to a constant 276 
inactivation rate.  277 
 278 
 279 
Figure 4. Lethal dose values calculated for 99.9% (3log10) and 100% (7log10 for 280 
bacteria and 5log10 for yeast). On the left (a), calculated lethal doses are presented 281 
for MB-APDT groups and on the right (b) they are presented for blue light 282 
inactivation. The presented values are means and standard errors obtained from 283 
data of at least three independent experiments. 284 
 285 
 A very useful aspect of using our proposed model is the ability to calculate 286 
lethal doses for any given level of survival fraction. Such information allows precise 287 
and direct comparisons in between experimental groups and also provides basis for 288 
future experimental planning. For example, if one is interested to analyze 289 
perspectives of microbial inactivation by APDT or blue light of different experimental 290 
groups at the same survival fraction level, this analysis can be used to establish the 291 
required light doses. Alternatively, this analysis can also calculate the dose required 292 
to achieve complete microbial inactivation (i.e., LD100), which is experimentally 293 
inviable to measure. In figure 4, we used data obtained from equation 1 (e.g., LD90 294 
and T values) to calculate LD99.9 and LD100 through equation 2. As expected, 295 
experimental groups with T < 1 presented much greater variations in between LD99.9 296 
and LD100 than groups with T > 1. The statistical results respective to data from 297 
figure 3 are presented in tables 6-7 from supplementary material. 298 
 For experimental verification of our proposed model, we compared 299 
photodynamic inactivation kinetics of MB-APDT and blue light using diverse species 300 
of clinically relevant pathogens. MB currently is the most broadly PS used in APDT 301 
studies while blue light inactivation is a promising antimicrobial platform using novel 302 
high-powered blue LEDs. These surrogates represent very different approaches to 303 
light-mediated microbial control and, yet, equation 1 successfully fit all tested data. 304 
We also showed that doses can be reported in time or energy units with no detriment 305 
of the analysis output. Thus, we expect that other PS classes should also be suitable 306 
for such analysis, and that this approach will allow the development of standardized 307 
protocols for photodynamic antimicrobial therapies. This way, future studies that 308 
choose to use our model could report quantitative data regarding LD90 and T values 309 
in order to allow comparative analysis in between different photoinactivation systems 310 
(i.e., different PS, light sources, irradiances, etc.).  311 
 312 
Conclusion 313 
 We reported a mathematical model to fit and describe photoinactivation 314 
kinetics in interpretative and quantitative terms. A power-law function successfully fit 315 
all data from experiments performed with MB-APDT and blue light alone. A deduced 316 
formula could also be used to precisely predict lethal doses for any given survival 317 
fraction value. We truly expect that these analytical methods may contribute to a 318 
more standardized protocol for comparisons of photodynamic inactivation efficiency. 319 
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Table 2. One-way ANOVA results for comparisons of T values of MB-APDT  400 
T value comparison Significant? Adjusted P Value 
E. coli vs. S. aureus No >0,9999 
E. coli vs. P. aeruginosa Yes 0,0184 
E. coli vs. K. pneumoniae Yes <0,0001 
E. coli vs. C. albicans Yes 0,0056 
S. aureus vs. P. aeruginosa Yes 0,0021 
S. aureus vs. K. pneumoniae Yes <0,0001 
S. aureus vs. C. albicans Yes 0,0007 
P. aeruginosa vs. K. pneumoniae Yes 0,0031 
P. aeruginosa vs. C. albicans No >0,9999 
K. pneumoniae vs. C. albicans Yes 0,0106 
 401 
 402 
Table 3. One-way ANOVA results for comparisons of T values of blue light  403 
T value comparison Significant? Adjusted P Value 
E. coli vs. S. aureus No >0,9999 
E. coli vs. P. aeruginosa No >0,9999 
E. coli vs. K. pneumoniae No >0,9999 
E. coli vs. C. albicans No >0,9999 
S. aureus vs. P. aeruginosa No >0,9999 
S. aureus vs. K. pneumoniae No >0,9999 
S. aureus vs. C. albicans No >0,9999 
P. aeruginosa vs. K. pneumoniae No >0,9999 
P. aeruginosa vs. C. albicans No 0,0831 
K. pneumoniae vs. C. albicans No 0,2932 
 404 
 405 
Table 4. One-way ANOVA results for comparisons of LD90 values of MB-APDT 406 
LD90 value comparison Significant? 
Adjusted P 
Value 
E. coli vs. S. aureus No >0,9999 
E. coli vs. P. aeruginosa Yes <0,0001 
E. coli vs. K. pneumoniae Yes <0,0001 
E. coli vs. C. albicans Yes <0,0001 
S. aureus vs. P. aeruginosa Yes <0,0001 
S. aureus vs. K. pneumoniae Yes <0,0001 
S. aureus vs. C. albicans Yes <0,0001 
P. aeruginosa vs. K. pneumoniae Yes <0,0001 
P. aeruginosa vs. C. albicans Yes <0,0001 
K. pneumoniae vs. C. albicans No >0,9999 
 407 
 408 
Table 5. One-way ANOVA results for comparisons of LD90 values of blue light 409 
LD value comparison Significant? 
Adjusted P 
Value 
E. coli vs. S. aureus No >0,9999 
E. coli vs. P. aeruginosa Yes 0,0116 
E. coli vs. K. pneumoniae Yes 0,0002 
E. coli vs. C. albicans Yes 0,0141 
S. aureus vs. P. aeruginosa No 0,0771 
S. aureus vs. K. pneumoniae Yes <0,0001 
S. aureus vs. C. albicans Yes 0,0025 
P. aeruginosa vs. K. pneumoniae Yes <0,0001 
P. aeruginosa vs. C. albicans Yes <0,0001 
K. pneumoniae vs. C. albicans No 0,0959 
 410 
Table 6. One-way ANOVA results for comparisons of LD99.9 and LD100 values of MB-411 
APDT 412 
  




E. coli vs. S. aureus No >0,9999 
E. coli vs. P. aeruginosa Yes <0,0001 
E. coli vs. K. pneumoniae Yes <0,0001 
E. coli vs. C. albicans Yes <0,0001 
S. aureus vs. P. aeruginosa Yes <0,0001 
S. aureus vs. K. pneumoniae Yes <0,0001 
S. aureus vs. C. albicans Yes <0,0001 
P. aeruginosa vs. K. pneumoniae Yes 0,0392 
P. aeruginosa vs. C. albicans Yes <0,0001 
K. pneumoniae vs. C. albicans Yes 0,0150 
LD100 
E. coli vs. S. aureus No >0,9999 
E. coli vs. P. aeruginosa Yes <0,0001 
E. coli vs. K. pneumoniae Yes <0,0001 
E. coli vs. C. albicans Yes <0,0001 
S. aureus vs. P. aeruginosa Yes <0,0001 
S. aureus vs. K. pneumoniae Yes <0,0001 
S. aureus vs. C. albicans Yes <0,0001 
P. aeruginosa vs. K. pneumoniae No 0,5517 
P. aeruginosa vs. C. albicans Yes <0,0001 
K. pneumoniae vs. C. albicans Yes 0,0006 
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Table 7. One-way ANOVA results for comparisons of LD99.9 and LD100 values of blue 414 
light 415 




E. coli vs. S. aureus No >0,9999 
E. coli vs. P. aeruginosa Yes 0,0221 
E. coli vs. K. pneumoniae Yes <0,0001 
E. coli vs. C. albicans Yes 0,0002 
S. aureus vs. P. aeruginosa No 0,1844 
S. aureus vs. K. pneumoniae Yes <0,0001 
S. aureus vs. C. albicans Yes <0,0001 
P. aeruginosa vs. K. pneumoniae Yes <0,0001 
P. aeruginosa vs. C. albicans Yes <0,0001 
K. pneumoniae vs. C. albicans No >0,9999 
LD100 
E. coli vs. S. aureus No 0,8517 
E. coli vs. P. aeruginosa Yes <0,0001 
E. coli vs. K. pneumoniae Yes <0,0001 
E. coli vs. C. albicans Yes <0,0001 
S. aureus vs. P. aeruginosa Yes 0,0001 
S. aureus vs. K. pneumoniae Yes <0,0001 
S. aureus vs. C. albicans Yes <0,0001 
P. aeruginosa vs. K. pneumoniae Yes <0,0001 
P. aeruginosa vs. C. albicans Yes <0,0001 
K. pneumoniae vs. C. albicans No >0,9999 
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